CoverMyMeds (McKesson) vs Infinx
Two Prior Authorization vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| CoverMyMeds (McKesson) | Infinx | |
|---|---|---|
| Pricing model | Free to providers (funded by payers/pharma) · Payers, PBMs, pharma fund the network | Enterprise contract (custom) · Software plus services, quote-based |
| Speed to go live | Free self-serve portal; EHR-embedded options exist | Standard EHR integration project |
| Automation model | Data / network utility · medication ePA network and portal | Tech-enabled service · AI agents plus expert staff |
| Built for | Small practices, Mid-size groups, Enterprise systems, Payers | Mid-size groups, Enterprise systems, Billing companies |
| Security posture | No certifications published | HITRUST, SOC 2 Type II, HIPAA |
| Company maturity | 18 yrs (est. 2008) | 14 yrs (est. 2012) |
| Financial backing | Subsidiary of McKesson | $186M reported · Growth (KKR minority stake 2024) |
| Named customers | None public | None public |
| Published results | No public numbers | No public numbers |
| Documented integrations | 5 listed | 5 listed |
| Third-party validation | None found | None found |
Bottom line
- Pick CoverMyMeds if you want free electronic prior auth for medications with the broadest payer and pharmacy network.
- Pick Infinx if you want prior auth and revenue cycle work handled by a blend of AI and human specialists rather than buying software your staff must run.
CoverMyMeds (McKesson)
The largest electronic prior authorization network for medications
- Founded
- 2008
- HQ
- Columbus, OH
- Stage
- Subsidiary of McKesson
- Raised
- n/a
What it does
- Electronic prior authorization for retail and specialty drugs
- Specialty enrollment and hub services (RxLightning)
- Medical benefit PA for oncology and radiology (FastAuth)
- Benefit checks and prescription price transparency
- Patient affordability and copay program delivery
Where it's strong
- Network effects are real: it completed 43 million prior authorizations in the 2025 reverification season and most prescribers already have accounts.
- Free for providers and pharmacies, which makes adoption easy.
- McKesson ownership ties it into specialty distribution and pharma services that competitors cannot match.
What buyers should weigh
- Coverage is payer-dependent and shifting: Independence Blue Cross dropped CoverMyMeds for Surescripts ePA in August 2025, so verify your payer mix routes through it.
- It centers on medication PA; medical benefit and procedure prior auth needs mostly require other tools despite the FastAuth acquisition.
- Its revenue comes from pharma and payers, so provider-side feature priorities can lag.
Integrations
Infinx
AI plus specialists for prior auth and patient access
- Founded
- 2012
- HQ
- San Jose, CA
- Stage
- Growth (KKR minority stake 2024)
- Raised
- $186M reported
What it does
- AI prior authorization determination, submission, and status tracking
- Eligibility verification and benefits checks in one platform
- Patient pay estimates before service
- Certified specialists work exceptions automation cannot resolve
- AR recovery and denial management services
Where it's strong
- The AI-plus-human model delivers completed authorizations, not just software your staff still has to work.
- Deep roots in high-volume prior auth specialties like radiology, labs, and cardiology.
- Trusted by more than 900 provider organizations, with KKR and Norwest backing.
What buyers should weigh
- Part of the value is outsourced labor, so compare its per-transaction economics against pure software options.
- Named customer references are rare in public materials; case studies are anonymized.
- Broad service catalog means implementation scope needs careful definition up front.
Integrations
Compare against the rest of Prior Authorization
Deciding between these two?
First Pass tracks Prior Authorization every week: funding, launches, and what changed since this page was written.